$MBIO
MUSTANG BIO, INC.

2018 Q4 Form 10-K Financial Statement

#000114420419014624 Filed on March 18, 2019

View on sec.gov

Income Statement

Concept 2018 Q4 2018 Q3 2018 Q2
Revenue -$50.00K $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.680M $1.340M $1.680M
YoY Change -46.15% -70.87% 0.6%
% of Gross Profit
Research & Development $10.22M $5.316M $3.557M
YoY Change -18.95% 963.2% 611.4%
% of Gross Profit
Depreciation & Amortization $310.0K $200.0K $115.0K
YoY Change
% of Gross Profit
Operating Expenses $11.90M $7.656M $5.240M
YoY Change -24.35% 8.07% -7.5%
Operating Profit -$11.85M -$7.656M -$5.240M
YoY Change -24.67% 8.07% -7.5%
Interest Expense $130.0K $140.0K $150.0K
YoY Change 0.0% 0.0% 7.14%
% of Operating Profit
Other Income/Expense, Net $130.0K $138.0K $147.0K
YoY Change 0.78% -4.17% 8.09%
Pretax Income -$11.77M -$7.520M -$5.090M
YoY Change -24.55% 8.36% -7.96%
Income Tax
% Of Pretax Income
Net Earnings -$11.77M -$7.518M -$5.093M
YoY Change -24.56% 8.33% -7.89%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$423.8K -$277.0K -$187.9K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q4 2018 Q3 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $34.10M $40.80M $46.70M
YoY Change -44.1% -39.38% -36.72%
Cash & Equivalents $16.97M $18.80M $12.24M
Short-Term Investments $17.60M $22.50M $35.00M
Other Short-Term Assets $1.000M $900.0K $1.000M
YoY Change 233.33% 125.0%
Inventory
Prepaid Expenses $1.015M $872.0K $965.0K
Receivables
Other Receivables $50.00K
Total Short-Term Assets $35.13M $41.83M $48.12M
YoY Change -42.76% -38.26% -34.8%
LONG-TERM ASSETS
Property, Plant & Equipment $6.858M $6.793M $6.536M
YoY Change 396.6% 4787.05%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $271.0K $394.0K $521.0K
YoY Change 7.97%
Total Long-Term Assets $7.629M $7.687M $7.557M
YoY Change 257.83% 5430.22%
TOTAL ASSETS
Total Short-Term Assets $35.13M $41.83M $48.12M
Total Long-Term Assets $7.629M $7.687M $7.557M
Total Assets $42.75M $49.51M $55.68M
YoY Change -32.66% -27.06% -24.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.600M $4.100M $3.700M
YoY Change 55.56% 46.43% -17.78%
Accrued Expenses $200.0K $300.0K $200.0K
YoY Change 100.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.617M $4.052M $3.675M
YoY Change 55.55% 44.71% -22.83%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $700.0K $500.0K $400.0K
YoY Change 600.0%
Total Long-Term Liabilities $700.0K $500.0K $400.0K
YoY Change 600.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.617M $4.052M $3.675M
Total Long-Term Liabilities $700.0K $500.0K $400.0K
Total Liabilities $6.358M $4.522M $4.070M
YoY Change 73.67% 61.96% -14.53%
SHAREHOLDERS EQUITY
Retained Earnings -$79.07M -$67.30M -$59.78M
YoY Change 63.34% 105.14% 131.11%
Common Stock $113.4M $112.3M $111.4M
YoY Change 14.9% 14.7% 17.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $36.40M $44.99M $51.61M
YoY Change
Total Liabilities & Shareholders Equity $42.75M $49.51M $55.68M
YoY Change -32.66% -27.06% -24.6%

Cashflow Statement

Concept 2018 Q4 2018 Q3 2018 Q2
OPERATING ACTIVITIES
Net Income -$11.77M -$7.518M -$5.093M
YoY Change -24.56% 8.33% -7.89%
Depreciation, Depletion And Amortization $310.0K $200.0K $115.0K
YoY Change
Cash From Operating Activities -$6.520M -$3.800M -$3.350M
YoY Change 26.11% -20.34% 245.36%
INVESTING ACTIVITIES
Capital Expenditures -$300.0K -$1.150M -$4.740M
YoY Change -25.0% 5650.0%
Acquisitions
YoY Change
Other Investing Activities $5.000M $11.50M $2.010M
YoY Change -36.14% -172.56% -109.94%
Cash From Investing Activities $4.700M $10.35M -$2.740M
YoY Change -36.83% -165.18% -86.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 80.00K
YoY Change -100.0% -900.0%
NET CHANGE
Cash From Operating Activities -6.520M -3.800M -3.350M
Cash From Investing Activities 4.700M 10.35M -2.740M
Cash From Financing Activities 0.000 0.000 80.00K
Net Change In Cash -1.820M 6.550M -6.010M
YoY Change -180.18% -131.83% -71.66%
FREE CASH FLOW
Cash From Operating Activities -$6.520M -$3.800M -$3.350M
Capital Expenditures -$300.0K -$1.150M -$4.740M
Free Cash Flow -$6.220M -$2.650M $1.390M
YoY Change 30.4% -44.21%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Liabilities
Liabilities
6358000
CY2017Q4 us-gaap Liabilities
Liabilities
3661000
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2017Q4 mbio Payables And Accruedexpenses Related Parties Current
PayablesAndAccruedexpensesRelatedPartiesCurrent
137000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5617000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3611000
CY2018Q4 us-gaap Accrued Rent Noncurrent
AccruedRentNoncurrent
741000
CY2017Q4 us-gaap Accrued Rent Noncurrent
AccruedRentNoncurrent
50000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2018Q4 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
2085000
CY2017Q4 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
9558000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
113378000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
98679000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-79070000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-48408000
CY2018Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
16469000
CY2017Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
34975000
CY2018Q4 us-gaap Other Short Term Investments
OtherShortTermInvestments
17604000
CY2017Q4 us-gaap Other Short Term Investments
OtherShortTermInvestments
26002000
CY2018Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
37000
CY2017Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
106000
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1015000
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
278000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
35125000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
61361000
CY2018Q4 mbio Property Plant And Equipment Excluding Assets Under Construction
PropertyPlantAndEquipmentExcludingAssetsUnderConstruction
6465000
CY2017Q4 mbio Property Plant And Equipment Excluding Assets Under Construction
PropertyPlantAndEquipmentExcludingAssetsUnderConstruction
140000
CY2018Q4 mbio Construction In Process Net
ConstructionInProcessNet
393000
CY2017Q4 mbio Construction In Process Net
ConstructionInProcessNet
1241000
CY2018Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
500000
CY2017Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
500000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
271000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
251000
CY2018Q4 us-gaap Assets
Assets
42754000
CY2017Q4 us-gaap Assets
Assets
63493000
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5381000
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3474000
CY2018Q4 mbio Payables And Accruedexpenses Related Parties Current
PayablesAndAccruedexpensesRelatedPartiesCurrent
236000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
36396000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
59832000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42754000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
63493000
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q1 us-gaap Revenues
Revenues
50000
CY2018Q2 us-gaap Revenues
Revenues
0
CY2018Q3 us-gaap Revenues
Revenues
0
CY2018Q4 us-gaap Revenues
Revenues
-50000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6477000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5240000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7656000
CY2018Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-11850000
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
146000
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
147000
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
138000
CY2018Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
130000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-6281000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-5093000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-7518000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-11770000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
CY2017Q1 us-gaap Revenues
Revenues
0
CY2017Q2 us-gaap Revenues
Revenues
0
CY2017Q3 us-gaap Revenues
Revenues
0
CY2017Q4 us-gaap Revenues
Revenues
0
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3306000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5665000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7084000
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-15730000
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
88000
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
136000
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
144000
CY2017Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
129000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-3218000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-5529000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-6940000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-15601000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.61
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26610183
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25236255
CY2018Q4 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
709314
CY2017Q4 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
834756
CY2018 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
21104000
CY2017 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
7943000
CY2018 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
3360000
CY2017Q4 mbio Deferred Tax Assets Start Up Costs
DeferredTaxAssetsStartUpCosts
8000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1070000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
178000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
23348000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
14615000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
23348000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
14615000
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26610183
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25236255
CY2017 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
12433000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6759000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11409000
CY2018 us-gaap Interest Income Other
InterestIncomeOther
569000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.07
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.09
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.02
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.03
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0
CY2018 mbio Effective Income Tax Rate Reconciliation Change In Federal Enacted Tax Ratepercent
EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatepercent
0
CY2017 mbio Effective Income Tax Rate Reconciliation Change In Federal Enacted Tax Ratepercent
EffectiveIncomeTaxRateReconciliationChangeInFederalEnactedTaxRatepercent
-0.18
CY2018 mbio Effective Income Tax Rate Reconciliation Change In State Enacted Tax Ratepercent
EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatepercent
-0.02
CY2017 mbio Effective Income Tax Rate Reconciliation Change In State Enacted Tax Ratepercent
EffectiveIncomeTaxRateReconciliationChangeInStateEnactedTaxRatepercent
-0.01
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.01
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.01
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.28
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.22
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
14305000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
7236000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
1427000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
697000
CY2018Q4 us-gaap Deferred Tax Assets Derivative Instruments
DeferredTaxAssetsDerivativeInstruments
45000
CY2017Q4 us-gaap Deferred Tax Assets Derivative Instruments
DeferredTaxAssetsDerivativeInstruments
50000
CY2018Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
6258000
CY2017Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
6424000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
237000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
22000
CY2018Q4 mbio Deferred Tax Assets Start Up Costs
DeferredTaxAssetsStartUpCosts
6000
CY2018 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0
CY2017 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
320000
CY2018 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0
CY2017 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
50296000
CY2018 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
181000
CY2017 us-gaap Interest Income Other
InterestIncomeOther
505000
CY2017 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2018 us-gaap Interest Expense Debt
InterestExpenseDebt
8000
CY2017 us-gaap Interest Expense Debt
InterestExpenseDebt
8000
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.14
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.24
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26949374
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25252832
CY2018 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
5700000
CY2018 mbio Decreased In Deferred Tax Assets
DecreasedInDeferredTaxAssets
5700000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-30662000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-31288000
CY2018 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
1275000
CY2017 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
2875000
CY2018 mbio Issuance Of Common Stock Founder Agreement Expenses
IssuanceOfCommonStockFounderAgreementExpenses
0
CY2017 mbio Issuance Of Common Stock Founder Agreement Expenses
IssuanceOfCommonStockFounderAgreementExpenses
1234000
CY2018 mbio Common Stock Issuable For Founder Agreement
CommonStockIssuableForFounderAgreement
2085000
CY2017 mbio Common Stock Issuable For Founder Agreement
CommonStockIssuableForFounderAgreement
9558000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
4960000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
2012000
CY2018 us-gaap Depreciation
Depreciation
630000
CY2017 us-gaap Depreciation
Depreciation
2000
CY2018 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0
CY2017 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
2062000
CY2018 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
757000
CY2017 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
278000
CY2018 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
35000
CY2017 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
106000
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2470000
CY2017 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1332000
CY2018 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
99000
CY2017 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
12000
CY2018 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0
CY2017 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-413000
CY2018 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-691000
CY2017 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-50000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35475000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27499000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16969000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
0
CY2017 us-gaap Interest Paid Net
InterestPaidNet
413000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
196000
CY2017 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
959000
CY2018 us-gaap Stock Issued1
StockIssued1
9558000
CY2017 us-gaap Stock Issued1
StockIssued1
4396000
CY2018 mbio Research Amd Development Licenses Expenditure Incurred But Not Yet Paid
ResearchAmdDevelopmentLicensesExpenditureIncurredButNotYetPaid
200000
CY2017 mbio Research Amd Development Licenses Expenditure Incurred But Not Yet Paid
ResearchAmdDevelopmentLicensesExpenditureIncurredButNotYetPaid
500000
CY2018 mbio Stock Issuable For License Acquired
StockIssuableForLicenseAcquired
0
CY2017 mbio Stock Issuable For License Acquired
StockIssuableForLicenseAcquired
1682000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
264000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
448000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
462000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
476000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
489000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
1458000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
3597000
CY2017Q4 mbio Number Of Shares To Be Issued Upon Legal Settlement
NumberOfSharesToBeIssuedUponLegalSettlement
200000
CY2017 us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
2000000
CY2017Q4 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
200000
CY2018 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2017 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
5674000
CY2017Q4 us-gaap Land Subject To Ground Leases
LandSubjectToGroundLeases
27043
CY2017Q4 us-gaap Operating Leases Rent Expense Sublease Rentals1
OperatingLeasesRentExpenseSubleaseRentals1
0.6
CY2017Q4 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
3.6
CY2017Q4 us-gaap Security Deposit
SecurityDeposit
800000
CY2017Q4 us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
1300000
CY2017 mbio Stock Issuance Common Stock Issuable During Period
StockIssuanceCommonStockIssuableDuringPeriod
9558000
CY2017 mbio Stock Issued During Period Value Issued For Founders Agreement
StockIssuedDuringPeriodValueIssuedForFoundersAgreement
1234000
CY2017 us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
1682000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
55970000
CY2017 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
5674000
CY2017 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2012000
CY2017 mbio Adjustment To Additional Paid In Capital Capital Contribution
AdjustmentToAdditionalPaidInCapitalCapitalContribution
2062000
CY2017 mbio Share Issued During Period Valueon Exercise Of Warrants
ShareIssuedDuringPeriodValueonExerciseOfWarrants
0
CY2018 mbio Stock Issuance Common Stock Issuable During Period
StockIssuanceCommonStockIssuableDuringPeriod
2085000
CY2018 mbio Stock Issued During Period Value Issued For Founders Agreement
StockIssuedDuringPeriodValueIssuedForFoundersAgreement
0
CY2018 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4960000
CY2018 mbio Share Issued During Period Valueon Exercise Of Warrants
ShareIssuedDuringPeriodValueonExerciseOfWarrants
181000
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates</div></div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.41in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018 mbio Potentially Dilutive Securities
PotentiallyDilutiveSecurities
8237093
CY2017 mbio Potentially Dilutive Securities
PotentiallyDilutiveSecurities
7058993
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7490000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1383000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
632000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6858000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1381000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
5.73
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2018Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
27600000
CY2017Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
40000000
CY2018Q4 mbio Property Plant And Equipment Design Costs Capitalized
PropertyPlantAndEquipmentDesignCostsCapitalized
400000
CY2019Q1 us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.020
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2100000
CY2018 us-gaap Common Stock Voting Rights
CommonStockVotingRights
1.1
CY2016Q2 mbio Additional Consideration Under Founders Agreement Description
AdditionalConsiderationUnderFoundersAgreementDescription
(i) pay an equity fee in shares of common stock, payable within five (5) business days of the closing of any equity or debt financing for Mustang that occurs after the effective date of the Mustang Founders Agreement and ending on the date when Fortress no longer has majority voting control in the Company&#8217;s voting equity, equal to two and one-half (2.5%) of the gross amount of any such equity or debt financing; and (ii) pay a cash fee equal to four and one-half percent (4.5%) of the Company&#8217;s annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a Change in Control, the Company will pay a one-time change in control fee equal to five (5x) times the product of (A) net sales for the twelve (12) months immediately preceding the change in control and (B) four and one-half percent (4.5%) (see Note 7).
CY2016Q2 mbio Founders Agreement Term
FoundersAgreementTerm
P15Y
CY2018 us-gaap Officers Compensation
OfficersCompensation
84000
CY2017 us-gaap Officers Compensation
OfficersCompensation
25052
CY2018Q4 us-gaap Business Acquisition Percentage Of Voting Interests Acquired
BusinessAcquisitionPercentageOfVotingInterestsAcquired
0.321
CY2016Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
601486
CY2018 mbio Annual Fees Expenses On Founders Agreement
AnnualFeesExpensesOnFoundersAgreement
500000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
34000
CY2016Q4 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
10000000
CY2017Q4 mbio Research And Development Expense Sponsored Research Payment
ResearchAndDevelopmentExpenseSponsoredResearchPayment
800000
CY2017Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1700000
CY2018Q3 mbio Maximum Value Of Shares Authorized
MaximumValueOfSharesAuthorized
75000000
CY2018Q3 mbio Commission Rate Percentage
CommissionRatePercentage
0.030
CY2017Q1 mbio Warrants Issued
WarrantsIssued
2134193
CY2017Q1 mbio Warrants Issued
WarrantsIssued
16000
CY2018Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
11.45
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
5.73
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
2049689
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5500000
CY2018Q3 mbio Revenue Recognition Milestone Method Payments Due
RevenueRecognitionMilestoneMethodPaymentsDue
13500000
CY2017Q2 mbio Payment Of Upfront Fees
PaymentOfUpfrontFees
600000
CY2017Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
50000
CY2017Q2 mbio Revenue Recognition Milestone Method Payments Due
RevenueRecognitionMilestoneMethodPaymentsDue
14900000
CY2017 mbio Annual Fees Expenses On Founders Agreement
AnnualFeesExpensesOnFoundersAgreement
500000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
The remaining 50% (the &#8220;Performance Options&#8221;) vest and become exercisable upon the occurrence of the following milestones being achieved: (i) 25% of the Performance Options vest upon the dosing of the first patient in the first Phase 2 clinical trial of any Company product candidate, (ii) 25% of the Performance Options vest upon the dosing of the first patient in the first Phase 2 clinical trial of a second Company product candidate, (iii) 25% of the Performance Options vest upon the Company&#8217;s achievement of a fully-diluted market capitalization of $500,000,000 and (iv) 25% of the Performance Options vest upon the Company&#8217;s achievement of a fully-diluted market capitalization of $1,000,000,000.
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
24276000
CY2018 us-gaap Operating Expenses
OperatingExpenses
31223000
CY2017 us-gaap Operating Expenses
OperatingExpenses
31785000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-31223000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-31785000
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
561000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
497000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
181000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
49976000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18506000
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7976000
CY2018 dei Document Type
DocumentType
10-K
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-12-31
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018 dei Entity Registrant Name
EntityRegistrantName
MUSTANG BIO, INC.
CY2018 dei Entity Central Index Key
EntityCentralIndexKey
0001680048
CY2018 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2018Q2 dei Entity Public Float
EntityPublicFloat
0
CY2018 dei Trading Symbol
TradingSymbol
MBIO
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2018 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2018 dei Entity Small Business
EntitySmallBusiness
true
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19244000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12948000
CY2018 us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
52500000
CY2018 us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
61002000
CY2018 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1075000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6870000
CY2018 mbio Payments For Security Depsots
PaymentsForSecurityDepsots
0
CY2017 us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
20000000
CY2017 us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
46002000
CY2017 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
2375000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
424000
CY2017 mbio Payments For Security Depsots
PaymentsForSecurityDepsots
251000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
557000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29052000

Files In Submission

Name View Source Status
0001144204-19-014624-index-headers.html Edgar Link pending
0001144204-19-014624-index.html Edgar Link pending
0001144204-19-014624.txt Edgar Link pending
0001144204-19-014624-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mbio-20181231.xml Edgar Link completed
mbio-20181231.xsd Edgar Link pending
mbio-20181231_cal.xml Edgar Link unprocessable
mbio-20181231_def.xml Edgar Link unprocessable
mbio-20181231_lab.xml Edgar Link unprocessable
mbio-20181231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv515572_10k.htm Edgar Link pending
tv515572_ex23-1.htm Edgar Link pending
tv515572_ex31-1.htm Edgar Link pending
tv515572_ex31-2.htm Edgar Link pending
tv515572_ex32-1.htm Edgar Link pending
tv515572_ex32-2.htm Edgar Link pending